T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy

Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application of these agents in the clinic is challenging due to immune complexity and heterogeneity. We interrogated transcriptomics of 15 TPMs (CD137, CD27,...

Full description

Saved in:
Bibliographic Details
Published inNpj genomic medicine Vol. 8; no. 1; p. 19
Main Authors Miyashita, Hirotaka, Kurzrock, Razelle, Bevins, Nicholas J., Thangathurai, Kartheeswaran, Lee, Suzanna, Pabla, Sarabjot, Nesline, Mary, Glenn, Sean T., Conroy, Jeffrey M., DePietro, Paul, Rubin, Eitan, Sicklick, Jason K., Kato, Shumei
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 08.08.2023
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application of these agents in the clinic is challenging due to immune complexity and heterogeneity. We interrogated transcriptomics of 15 TPMs (CD137, CD27, CD28, CD80, CD86, CD40, CD40LG, GITR, ICOS, ICOSLG, OX40, OX40LG, GZMB, IFNG, and TBX21) in a pan-cancer cohort ( N  = 514 patients, 30 types of cancer). TPM expression was analyzed for correlation with histological type, microsatellite instability high (MSI-H), tumor mutational burden (TMB), and programmed death-ligand 1 (PD-L1) expression. Among 514 patients, the most common histological types were colorectal (27%), pancreatic (11%), and breast cancer (10%). No statistically significant association between histological type and TPM expression was seen. In contrast, expression of GZMB (granzyme B, a serine protease stored in activated T and NK cells that induces cancer cell apoptosis) and IFNG (activates cytotoxic T cells) were significantly higher in tumors with MSI-H, TMB ≥ 10 mutations/mb and PD-L1 ≥ 1%. PD-L1 ≥ 1% was also associated with significantly higher CD137, GITR, and ICOS expression. Patients’ tumors were classified into “Hot”, “Mixed”, or “Cold” clusters based on TPM expression using hierarchical clustering. The cold cluster showed a significantly lower proportion of tumors with PD-L1 ≥ 1%. Overall, 502 patients (98%) had individually distinct patterns of TPM expression. Diverse expression patterns of TPMs independent of histological type but correlating with other immunotherapy biomarkers (PD-L1 ≥ 1%, MSI-H and TMB ≥ 10 mutations/mb) were observed. Individualized selection of patients based on TPM immunomic profiles may potentially help with immunotherapy optimization.
AbstractList Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application of these agents in the clinic is challenging due to immune complexity and heterogeneity. We interrogated transcriptomics of 15 TPMs (CD137, CD27, CD28, CD80, CD86, CD40, CD40LG, GITR, ICOS, ICOSLG, OX40, OX40LG, GZMB, IFNG, and TBX21) in a pan-cancer cohort ( N  = 514 patients, 30 types of cancer). TPM expression was analyzed for correlation with histological type, microsatellite instability high (MSI-H), tumor mutational burden (TMB), and programmed death-ligand 1 (PD-L1) expression. Among 514 patients, the most common histological types were colorectal (27%), pancreatic (11%), and breast cancer (10%). No statistically significant association between histological type and TPM expression was seen. In contrast, expression of GZMB (granzyme B, a serine protease stored in activated T and NK cells that induces cancer cell apoptosis) and IFNG (activates cytotoxic T cells) were significantly higher in tumors with MSI-H, TMB ≥ 10 mutations/mb and PD-L1 ≥ 1%. PD-L1 ≥ 1% was also associated with significantly higher CD137, GITR, and ICOS expression. Patients’ tumors were classified into “Hot”, “Mixed”, or “Cold” clusters based on TPM expression using hierarchical clustering. The cold cluster showed a significantly lower proportion of tumors with PD-L1 ≥ 1%. Overall, 502 patients (98%) had individually distinct patterns of TPM expression. Diverse expression patterns of TPMs independent of histological type but correlating with other immunotherapy biomarkers (PD-L1 ≥ 1%, MSI-H and TMB ≥ 10 mutations/mb) were observed. Individualized selection of patients based on TPM immunomic profiles may potentially help with immunotherapy optimization.
Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application of these agents in the clinic is challenging due to immune complexity and heterogeneity. We interrogated transcriptomics of 15 TPMs (CD137, CD27, CD28, CD80, CD86, CD40, CD40LG, GITR, ICOS, ICOSLG, OX40, OX40LG, GZMB, IFNG, and TBX21) in a pan-cancer cohort (N = 514 patients, 30 types of cancer). TPM expression was analyzed for correlation with histological type, microsatellite instability high (MSI-H), tumor mutational burden (TMB), and programmed death-ligand 1 (PD-L1) expression. Among 514 patients, the most common histological types were colorectal (27%), pancreatic (11%), and breast cancer (10%). No statistically significant association between histological type and TPM expression was seen. In contrast, expression of GZMB (granzyme B, a serine protease stored in activated T and NK cells that induces cancer cell apoptosis) and IFNG (activates cytotoxic T cells) were significantly higher in tumors with MSI-H, TMB ≥ 10 mutations/mb and PD-L1 ≥ 1%. PD-L1 ≥ 1% was also associated with significantly higher CD137, GITR, and ICOS expression. Patients' tumors were classified into "Hot", "Mixed", or "Cold" clusters based on TPM expression using hierarchical clustering. The cold cluster showed a significantly lower proportion of tumors with PD-L1 ≥ 1%. Overall, 502 patients (98%) had individually distinct patterns of TPM expression. Diverse expression patterns of TPMs independent of histological type but correlating with other immunotherapy biomarkers (PD-L1 ≥ 1%, MSI-H and TMB ≥ 10 mutations/mb) were observed. Individualized selection of patients based on TPM immunomic profiles may potentially help with immunotherapy optimization.
Abstract Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application of these agents in the clinic is challenging due to immune complexity and heterogeneity. We interrogated transcriptomics of 15 TPMs (CD137, CD27, CD28, CD80, CD86, CD40, CD40LG, GITR, ICOS, ICOSLG, OX40, OX40LG, GZMB, IFNG, and TBX21) in a pan-cancer cohort (N = 514 patients, 30 types of cancer). TPM expression was analyzed for correlation with histological type, microsatellite instability high (MSI-H), tumor mutational burden (TMB), and programmed death-ligand 1 (PD-L1) expression. Among 514 patients, the most common histological types were colorectal (27%), pancreatic (11%), and breast cancer (10%). No statistically significant association between histological type and TPM expression was seen. In contrast, expression of GZMB (granzyme B, a serine protease stored in activated T and NK cells that induces cancer cell apoptosis) and IFNG (activates cytotoxic T cells) were significantly higher in tumors with MSI-H, TMB ≥ 10 mutations/mb and PD-L1 ≥ 1%. PD-L1 ≥ 1% was also associated with significantly higher CD137, GITR, and ICOS expression. Patients’ tumors were classified into “Hot”, “Mixed”, or “Cold” clusters based on TPM expression using hierarchical clustering. The cold cluster showed a significantly lower proportion of tumors with PD-L1 ≥ 1%. Overall, 502 patients (98%) had individually distinct patterns of TPM expression. Diverse expression patterns of TPMs independent of histological type but correlating with other immunotherapy biomarkers (PD-L1 ≥ 1%, MSI-H and TMB ≥ 10 mutations/mb) were observed. Individualized selection of patients based on TPM immunomic profiles may potentially help with immunotherapy optimization.
ArticleNumber 19
Author Nesline, Mary
Rubin, Eitan
Kato, Shumei
Glenn, Sean T.
Sicklick, Jason K.
Conroy, Jeffrey M.
Thangathurai, Kartheeswaran
Miyashita, Hirotaka
Kurzrock, Razelle
Bevins, Nicholas J.
Pabla, Sarabjot
Lee, Suzanna
DePietro, Paul
Author_xml – sequence: 1
  givenname: Hirotaka
  orcidid: 0000-0002-0433-9779
  surname: Miyashita
  fullname: Miyashita, Hirotaka
  email: miyashita.hirotaka@gmail.com
  organization: Department of Hematology and Oncology, Dartmouth Cancer Center
– sequence: 2
  givenname: Razelle
  orcidid: 0000-0003-4110-1214
  surname: Kurzrock
  fullname: Kurzrock, Razelle
  organization: Worldwide Innovative Network (WIN) for Personalized Cancer Therapy, Division of Hematology and Oncology, Medical College of Wisconsin
– sequence: 3
  givenname: Nicholas J.
  surname: Bevins
  fullname: Bevins, Nicholas J.
  organization: Department of Pathology, University of California San Diego
– sequence: 4
  givenname: Kartheeswaran
  orcidid: 0000-0001-7265-3922
  surname: Thangathurai
  fullname: Thangathurai, Kartheeswaran
  organization: The Shraga Segal Department for Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, Department of Physical Science, University of Vavuniya
– sequence: 5
  givenname: Suzanna
  surname: Lee
  fullname: Lee, Suzanna
  organization: Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC, San Diego Moores Cancer Center
– sequence: 6
  givenname: Sarabjot
  surname: Pabla
  fullname: Pabla, Sarabjot
  organization: OmniSeq Inc
– sequence: 7
  givenname: Mary
  surname: Nesline
  fullname: Nesline, Mary
  organization: OmniSeq Inc
– sequence: 8
  givenname: Sean T.
  surname: Glenn
  fullname: Glenn, Sean T.
  organization: Roswell Park Comprehensive Cancer Center, Center for Personalized Medicine
– sequence: 9
  givenname: Jeffrey M.
  surname: Conroy
  fullname: Conroy, Jeffrey M.
  organization: OmniSeq Inc
– sequence: 10
  givenname: Paul
  surname: DePietro
  fullname: DePietro, Paul
  organization: OmniSeq Inc
– sequence: 11
  givenname: Eitan
  surname: Rubin
  fullname: Rubin, Eitan
  organization: The Shraga Segal Department for Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev
– sequence: 12
  givenname: Jason K.
  surname: Sicklick
  fullname: Sicklick, Jason K.
  organization: Division of Surgical Oncology, Department of Surgery, and Center for Personalized Cancer Therapy, University of California, San Diego
– sequence: 13
  givenname: Shumei
  surname: Kato
  fullname: Kato, Shumei
  email: smkato@health.ucsd.edu
  organization: Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC, San Diego Moores Cancer Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37553332$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1TAQRiNURB_0D7BAkdiwCdgZO3HYIFRBqVSJTVlbjjPO9SWxg50g3X-P01xKy4KVX8fHntF3np047zDLXlHyjhIQ7yOjvOQFKaEgBHhTiGfZWUl4VdQNYyeP5qfZZYx7QgitOKVl8yI7hZpzACjPMntXaByGfAp2tK7P56Bc1MFOsx-tzkcVfmCIH3I7ToPVarbexdybtB4X50fMdzhj8D06tPMhNz4kFWobE3iE5h0GNR1eZs-NGiJeHseL7PuXz3dXX4vbb9c3V59uC80ZnQsFUGlQhhngpOoMaERius5ooJzoijODggtKUZjaYAe0qhTqWjBjRKsoXGQ3m7fzai_XulQ4SK-svN_woZcqzFYPKJu26UitBIpWsLZqlALV8Q46RjUFFMn1cXNNSztip9Gl_gxPpE9PnN3J3v-SlDDS1BVJhrdHQ_A_F4yzHG1cO64c-iXKUjBRlg2hkNA3_6B7vwSXerVSNa9oDU2iyo3SwccY0Dz8hhK5JkNuyZApGfI-GXKt4_XjOh6u_MlBAmADYjpyPYa_b_9H-xsossll
CitedBy_id crossref_primary_10_1007_s10555_024_10184_9
crossref_primary_10_3390_ijms25094742
crossref_primary_10_3389_fimmu_2024_1413956
crossref_primary_10_1016_j_isci_2024_109632
crossref_primary_10_1016_j_jds_2024_05_004
Cites_doi 10.1634/theoncologist.2009-0250
10.1080/21645515.2015.1009814
10.2217/fon-2020-0655
10.1158/1078-0432.CCR-17-1970
10.1158/1535-7163.MCT-17-0386
10.1080/2162402X.2019.1708065
10.1016/j.annonc.2020.04.011
10.1158/0008-5472.CAN-16-3346
10.4049/jimmunol.162.8.4983
10.1080/01621459.1963.10500845
10.1016/S1470-2045(20)30445-9
10.1111/j.1365-2559.2011.03915.x
10.1016/j.ygyno.2016.03.008
10.1056/NEJMoa1501824
10.1136/jitc-2019-000438
10.1016/j.ejca.2016.06.028
10.1016/j.intimp.2018.10.045
10.1158/0008-5472.CAN-12-3450
10.1111/1759-7714.13207
10.1056/NEJMoa0909530
10.1056/NEJMoa1809064
10.1097/COC.0b013e3182467d90
10.1016/S0140-6736(18)32409-7
10.1002/1878-0261.12748
10.1200/JCO.1999.17.7.2105
10.1016/j.jmoldx.2017.10.001
10.1038/s41379-020-0550-z
10.1158/1078-0432.CCR-16-2655
10.1016/j.annonc.2020.07.002
10.1016/S0140-6736(20)32714-8
10.1517/14712591003596318
10.1016/j.semcdb.2016.09.008
10.3390/cancers12030738
10.1038/s41575-019-0126-x
10.1080/2162402X.2018.1550341
10.1016/j.ccell.2020.10.001
10.1038/s41591-018-0136-1
10.1056/NEJMoa1003466
10.1056/NEJMoa2017699
10.1038/cdd.2009.206
10.1038/nbt0308-303
10.1016/S1470-2045(22)00128-0
10.1016/j.celrep.2017.04.031
10.1016/j.cell.2021.01.002
10.18637/jss.v061.i06
10.1093/bib/bbaa180
10.1016/j.immuni.2018.03.023
10.1080/2162402X.2020.1760067
10.1158/1078-0432.CCR-15-0263
10.1001/jama.290.16.2149
10.1038/s43018-021-00247-z
10.1007/s00428-005-0066-4
10.1186/s40425-019-0770-2
10.1056/NEJMoa1503093
10.1084/jem.20130590
10.1158/1535-7163.MCT-14-0983
10.1101/cshperspect.a028480
10.1016/j.immuni.2016.04.020
10.1016/S0140-6736(17)33297-X
10.1016/S0140-6736(20)30934-X
10.1016/j.jtho.2019.01.024
10.1056/NEJMoa063842
10.1056/NEJMoa1606774
10.1080/2162402X.2017.1284719
10.1001/jamaoncol.2018.0013
ContentType Journal Article
Copyright The Author(s) 2023
2023. Springer Nature Limited and Centre of Excellence in Genomic Medicine Research, King Abdulaziz University.
The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Springer Nature Limited and Centre of Excellence in Genomic Medicine Research, King Abdulaziz University 2023
Copyright_xml – notice: The Author(s) 2023
– notice: 2023. Springer Nature Limited and Centre of Excellence in Genomic Medicine Research, King Abdulaziz University.
– notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Springer Nature Limited and Centre of Excellence in Genomic Medicine Research, King Abdulaziz University 2023
DBID C6C
NPM
AAYXX
CITATION
3V.
7T3
7X7
7XB
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M7P
P64
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1038/s41525-023-00359-8
DatabaseName SpringerOpen
PubMed
CrossRef
ProQuest Central (Corporate)
Human Genome Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
Biological Science Database
Biotechnology and BioEngineering Abstracts
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
ProQuest Central Student
Technology Research Database
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
Human Genome Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
CrossRef


PubMed
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: SpringerOpen website
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2056-7944
EndPage 19
ExternalDocumentID oai_doaj_org_article_9b9d07a8e8b84b69aa3ad5d3d41c13e8
10_1038_s41525_023_00359_8
37553332
Genre Journal Article
GrantInformation_xml – fundername: NIH P30 CA023100
– fundername: ;
GroupedDBID 0R~
3V.
53G
5VS
7X7
8FI
8FJ
AAJSJ
ABUWG
ACGFS
ACSMW
ADBBV
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
EBLON
EBS
EMOBN
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HYE
M7P
M~E
NAO
NO~
OK1
PGMZT
PIMPY
PQQKQ
PROAC
RNT
RPM
SNYQT
UKHRP
NPM
AAYXX
CITATION
7T3
7XB
8FD
8FE
8FH
8FK
AZQEC
DWQXO
FR3
GNUQQ
K9.
LK8
P64
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c541t-a336c3af4f3506df3cee0fddfc3150c654fe85811e8f7fed3166aec784ff8ba13
IEDL.DBID RPM
ISSN 2056-7944
IngestDate Tue Oct 22 15:15:00 EDT 2024
Tue Sep 17 21:31:48 EDT 2024
Sat Oct 05 05:26:02 EDT 2024
Thu Oct 10 18:08:58 EDT 2024
Fri Nov 22 01:30:16 EST 2024
Sat Sep 28 08:10:59 EDT 2024
Fri Oct 11 20:45:40 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2023. Springer Nature Limited and Centre of Excellence in Genomic Medicine Research, King Abdulaziz University.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c541t-a336c3af4f3506df3cee0fddfc3150c654fe85811e8f7fed3166aec784ff8ba13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-0433-9779
0000-0003-4110-1214
0000-0001-7265-3922
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10409760/
PMID 37553332
PQID 2847561739
PQPubID 2041923
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_9b9d07a8e8b84b69aa3ad5d3d41c13e8
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10409760
proquest_miscellaneous_2848229013
proquest_journals_2847561739
crossref_primary_10_1038_s41525_023_00359_8
pubmed_primary_37553332
springer_journals_10_1038_s41525_023_00359_8
PublicationCentury 2000
PublicationDate 2023-08-08
PublicationDateYYYYMMDD 2023-08-08
PublicationDate_xml – month: 08
  year: 2023
  text: 2023-08-08
  day: 08
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Npj genomic medicine
PublicationTitleAbbrev npj Genom. Med
PublicationTitleAlternate NPJ Genom Med
PublicationYear 2023
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Reck (CR10) 2016; 375
Chen (CR36) 2021; 20
Hodi (CR3) 2010; 363
Lindner (CR55) 2013; 73
Larimer (CR38) 2017; 77
Patel, Kurzrock (CR11) 2015; 14
Summers, Cohen, Keegan, Pazdur (CR1) 2010; 15
André (CR14) 2020; 383
Westcott (CR27) 2021; 2
Wang, Zhu, Zhang, Wang (CR33) 2017; 64
Kato (CR28) 2020; 9
Litchfield (CR13) 2021; 184
Gao (CR34) 2020; 9
Chiaravalli (CR41) 2006; 448
Chen (CR47) 2019; 7
Jardim, de Melo Gagliato, Giles, Kurzrock (CR8) 2018; 24
Powles (CR5) 2018; 391
Zhu (CR51) 2020; 33
Bhat, Czuczman (CR59) 2010; 10
Boichard (CR20) 2019; 8
Zheng (CR58) 1999; 162
Webb, Milne, Kroeger, Nelson (CR43) 2016; 141
Charrad, Ghazzali, Boiteau, Niknafs (CR68) 2014; 61
Thorsson (CR12) 2018; 48
Wang, Wang, Xu, Zhang, Cao (CR45) 2019; 19
Fan, Quezada, Sepulveda, Sharma, Allison (CR52) 2014; 211
Fu (CR60) 2020; 12
Vano (CR29) 2022; 23
Conroy (CR64) 2018; 20
Jardim, Goodman, de Melo Gagliato, Kurzrock (CR16) 2021; 39
Kim (CR35) 2013; 36
Knee, Hewes, Brogdon (CR50) 2016; 67
Goodman (CR15) 2017; 16
Horn (CR23) 2018; 379
Ganesh (CR22) 2019; 16
Gutzmer (CR24) 2020; 395
Vaddepally, Kharel, Pandey, Garje, Chandra (CR6) 2020; 12
Derks (CR31) 2020; 31
Gong (CR42) 2019; 14
Boichard, Tsigelny, Kurzrock (CR21) 2017; 6
Ward (CR30) 1963; 58
Salama, Phillips, Platell, Iacopetta (CR39) 2011; 59
Esensten, Helou, Chopra, Weiss, Bluestone (CR56) 2016; 44
Alspach, Lussier, Schreiber (CR44) 2019; 11
Kasherman, Ahrari, Lheureux (CR7) 2021; 17
Garcia-Diaz (CR46) 2017; 19
Suntharalingam (CR57) 2006; 355
Marabelle (CR66) 2020; 21
Okamura (CR18) 2020; 8
CR54
Baas (CR25) 2021; 397
Ringnér (CR69) 2008; 26
Robert (CR4) 2015; 372
Maemondo (CR63) 2010; 362
Seledtsov, Goncharov, Seledtsova (CR26) 2015; 11
Jiang (CR61) 2018; 24
Garon (CR9) 2015; 372
Kris (CR62) 2003; 290
Zhang (CR53) 2019; 66
CR67
Atkins (CR2) 1999; 17
CR65
Wang (CR49) 2019; 10
Subbiah, Solit, Chan, Kurzrock (CR17) 2020; 31
Cullen, Brunet, Martin (CR37) 2010; 17
Fuchs (CR32) 2018; 4
Yonezawa, Dutt, Chester, Kim, Kohrt (CR48) 2015; 21
Pham (CR19) 2020; 14
Pakish (CR40) 2017; 23
M Ringnér (359_CR69) 2008; 26
AM Goodman (359_CR15) 2017; 16
A Yonezawa (359_CR48) 2015; 21
RK Vaddepally (359_CR6) 2020; 12
Y Gao (359_CR34) 2020; 9
CS Fuchs (359_CR32) 2018; 4
JH Esensten (359_CR56) 2016; 44
DA Knee (359_CR50) 2016; 67
M Charrad (359_CR68) 2014; 61
YP Chen (359_CR36) 2021; 20
S Lindner (359_CR55) 2013; 73
J Fu (359_CR60) 2020; 12
X Fan (359_CR52) 2014; 211
A Boichard (359_CR21) 2017; 6
M Maemondo (359_CR63) 2010; 362
DL Jardim (359_CR16) 2021; 39
MMT Zhu (359_CR51) 2020; 33
V Thorsson (359_CR12) 2018; 48
JH Ward (359_CR30) 1963; 58
YA Vano (359_CR29) 2022; 23
M Zhang (359_CR53) 2019; 66
J Summers (359_CR1) 2010; 15
S Kato (359_CR28) 2020; 9
C Robert (359_CR4) 2015; 372
TV Pham (359_CR19) 2020; 14
S Bhat (359_CR59) 2010; 10
359_CR65
T André (359_CR14) 2020; 383
A Garcia-Diaz (359_CR46) 2017; 19
S Derks (359_CR31) 2020; 31
H Wang (359_CR45) 2019; 19
AM Chiaravalli (359_CR41) 2006; 448
M Reck (359_CR10) 2016; 375
SP Cullen (359_CR37) 2010; 17
359_CR67
P Baas (359_CR25) 2021; 397
A Marabelle (359_CR66) 2020; 21
L Wang (359_CR33) 2017; 64
JB Pakish (359_CR40) 2017; 23
P Jiang (359_CR61) 2018; 24
V Subbiah (359_CR17) 2020; 31
JR Webb (359_CR43) 2016; 141
BM Larimer (359_CR38) 2017; 77
MG Kris (359_CR62) 2003; 290
V Seledtsov (359_CR26) 2015; 11
H Wang (359_CR49) 2019; 10
359_CR54
D Jardim (359_CR8) 2018; 24
K Ganesh (359_CR22) 2019; 16
E Alspach (359_CR44) 2019; 11
S Chen (359_CR47) 2019; 7
EB Garon (359_CR9) 2015; 372
XX Zheng (359_CR58) 1999; 162
SP Patel (359_CR11) 2015; 14
FS Hodi (359_CR3) 2010; 363
L Kasherman (359_CR7) 2021; 17
P Salama (359_CR39) 2011; 59
K Litchfield (359_CR13) 2021; 184
G Suntharalingam (359_CR57) 2006; 355
T Powles (359_CR5) 2018; 391
R Okamura (359_CR18) 2020; 8
ST Kim (359_CR35) 2013; 36
L Horn (359_CR23) 2018; 379
R Gutzmer (359_CR24) 2020; 395
PMK Westcott (359_CR27) 2021; 2
JM Conroy (359_CR64) 2018; 20
A Boichard (359_CR20) 2019; 8
MB Atkins (359_CR2) 1999; 17
Z Gong (359_CR42) 2019; 14
References_xml – volume: 16
  start-page: 361
  year: 2019
  end-page: 375
  ident: CR22
  article-title: Immunotherapy in colorectal cancer: rationale, challenges and potential
  publication-title: Nat. Rev. Gastroenterol. Hepatol.
  contributor:
    fullname: Ganesh
– volume: 162
  start-page: 4983
  year: 1999
  end-page: 4990
  ident: CR58
  article-title: CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment - PubMed
  publication-title: J. Immunol.
  contributor:
    fullname: Zheng
– volume: 31
  start-page: 1115
  year: 2020
  end-page: 1118
  ident: CR17
  article-title: The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians
  publication-title: Ann. Oncol.
  contributor:
    fullname: Kurzrock
– volume: 23
  start-page: 612
  year: 2022
  end-page: 624
  ident: CR29
  article-title: Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
  publication-title: Lancet Oncol.
  contributor:
    fullname: Vano
– volume: 66
  start-page: 127
  year: 2019
  end-page: 138
  ident: CR53
  article-title: PD-1 blockade augments humoral immunity through ICOS-mediated CD4+ T cell instruction
  publication-title: Int. Immunopharmacol.
  contributor:
    fullname: Zhang
– volume: 141
  start-page: 293
  year: 2016
  end-page: 302
  ident: CR43
  article-title: PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
  publication-title: Gynecol. Oncol.
  contributor:
    fullname: Nelson
– volume: 21
  start-page: 1353
  year: 2020
  end-page: 1365
  ident: CR66
  article-title: Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
  publication-title: Lancet Oncol.
  contributor:
    fullname: Marabelle
– ident: CR54
– volume: 8
  start-page: e000438
  year: 2020
  ident: CR18
  article-title: ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
  publication-title: J. Immunother. Cancer
  contributor:
    fullname: Okamura
– volume: 20
  year: 2021
  ident: CR36
  article-title: Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses
  publication-title: Mol. Cancer
  contributor:
    fullname: Chen
– volume: 23
  start-page: 4473
  year: 2017
  end-page: 4481
  ident: CR40
  article-title: Immune microenvironment in microsatellite-instable endometrial cancers: Hereditary or sporadic origin matters
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Pakish
– volume: 19
  year: 2019
  ident: CR45
  article-title: Analysis of the transcriptomic features of microsatellite instability subtype colon cancer
  publication-title: BMC Cancer
  contributor:
    fullname: Cao
– volume: 39
  start-page: 154
  year: 2021
  end-page: 173
  ident: CR16
  article-title: The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
  publication-title: Cancer Cell
  contributor:
    fullname: Kurzrock
– volume: 77
  start-page: 2318
  year: 2017
  end-page: 2327
  ident: CR38
  article-title: Granzyme B PET imaging as a predictive biomarker of immunotherapy response
  publication-title: Cancer Res.
  contributor:
    fullname: Larimer
– volume: 59
  start-page: 207
  year: 2011
  end-page: 215
  ident: CR39
  article-title: Low expression of Granzyme B in colorectal cancer is associated with signs of early metastastic invasion
  publication-title: Histopathology
  contributor:
    fullname: Iacopetta
– volume: 61
  start-page: 1
  year: 2014
  end-page: 36
  ident: CR68
  article-title: NbClust: An R Package for Determining the Relevant Number of Clusters in a Data Set
  publication-title: J. Stat. Softw.
  contributor:
    fullname: Niknafs
– volume: 64
  start-page: 90
  year: 2017
  end-page: 97
  ident: CR33
  article-title: Roles of immune microenvironment heterogeneity in therapy-associated biomarkers in lung cancer
  publication-title: Semin Cell Dev. Biol.
  contributor:
    fullname: Wang
– volume: 12
  start-page: 738
  year: 2020
  ident: CR6
  article-title: Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence
  publication-title: Cancers (Basel)
  contributor:
    fullname: Chandra
– volume: 15
  start-page: 104
  year: 2010
  end-page: 111
  ident: CR1
  article-title: FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma
  publication-title: Oncologist
  contributor:
    fullname: Pazdur
– volume: 355
  start-page: 1018
  year: 2006
  end-page: 1028
  ident: CR57
  article-title: Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
  publication-title: N. Engl. J. Med.
  contributor:
    fullname: Suntharalingam
– ident: CR67
– volume: 44
  start-page: 973
  year: 2016
  end-page: 988
  ident: CR56
  article-title: CD28 Costimulation: From Mechanism to Therapy
  publication-title: Immunity
  contributor:
    fullname: Bluestone
– volume: 375
  start-page: 1823
  year: 2016
  end-page: 1833
  ident: CR10
  article-title: Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
  publication-title: N. Engl. J. Med.
  contributor:
    fullname: Reck
– volume: 6
  start-page: e1284719
  year: 2017
  ident: CR21
  article-title: High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
  publication-title: Oncoimmunology
  contributor:
    fullname: Kurzrock
– volume: 26
  start-page: 303
  year: 2008
  end-page: 304
  ident: CR69
  article-title: What is principal component analysis?
  publication-title: Nat. Biotechnol.
  contributor:
    fullname: Ringnér
– volume: 14
  start-page: 1680
  year: 2020
  end-page: 1694
  ident: CR19
  article-title: Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
  publication-title: Mol. Oncol.
  contributor:
    fullname: Pham
– volume: 383
  start-page: 2207
  year: 2020
  end-page: 2218
  ident: CR14
  article-title: Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
  publication-title: N. Engl. J. Med.
  contributor:
    fullname: André
– volume: 67
  start-page: 1
  year: 2016
  end-page: 10
  ident: CR50
  article-title: Rationale for anti-GITR cancer immunotherapy
  publication-title: Eur. J. Cancer
  contributor:
    fullname: Brogdon
– volume: 379
  start-page: 2220
  year: 2018
  end-page: 2229
  ident: CR23
  article-title: First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
  publication-title: N. Engl. J. Med.
  contributor:
    fullname: Horn
– volume: 14
  start-page: 857
  year: 2019
  end-page: 866
  ident: CR42
  article-title: Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma
  publication-title: J. Thorac. Oncol.
  contributor:
    fullname: Gong
– volume: 8
  start-page: 1550341
  year: 2019
  ident: CR20
  article-title: APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy
  publication-title: Oncoimmunology
  contributor:
    fullname: Boichard
– volume: 16
  start-page: 2598
  year: 2017
  end-page: 2608
  ident: CR15
  article-title: Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers
  publication-title: Mol. Cancer Ther.
  contributor:
    fullname: Goodman
– volume: 58
  start-page: 236
  year: 1963
  end-page: 244
  ident: CR30
  article-title: Hierarchical Grouping to Optimize an Objective Function
  publication-title: J. Am. Stat. Assoc.
  contributor:
    fullname: Ward
– volume: 9
  start-page: 1760067
  year: 2020
  ident: CR34
  article-title: Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study
  publication-title: Oncoimmunology
  contributor:
    fullname: Gao
– volume: 33
  start-page: 1753
  year: 2020
  end-page: 1763
  ident: CR51
  article-title: Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types
  publication-title: Mod. Pathol.
  contributor:
    fullname: Zhu
– volume: 11
  start-page: a028480
  year: 2019
  ident: CR44
  article-title: Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity
  publication-title: Cold Spring Harb. Perspect. Biol.
  contributor:
    fullname: Schreiber
– volume: 184
  start-page: 596
  year: 2021
  ident: CR13
  article-title: Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
  publication-title: Cell
  contributor:
    fullname: Litchfield
– volume: 17
  start-page: 616
  year: 2010
  end-page: 623
  ident: CR37
  article-title: Granzymes in cancer and immunity
  publication-title: Cell Death Differ.
  contributor:
    fullname: Martin
– volume: 11
  start-page: 851
  year: 2015
  end-page: 869
  ident: CR26
  article-title: Clinically feasible approaches to potentiating cancer cell-based immunotherapies
  publication-title: Hum. Vaccin. Immunother.
  contributor:
    fullname: Seledtsova
– volume: 36
  start-page: 224
  year: 2013
  end-page: 231
  ident: CR35
  article-title: Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer
  publication-title: Am. J. Clin. Oncol. Cancer Clin. Trials
  contributor:
    fullname: Kim
– volume: 391
  start-page: 748
  year: 2018
  end-page: 757
  ident: CR5
  article-title: Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
  publication-title: Lancet
  contributor:
    fullname: Powles
– volume: 2
  start-page: 1071
  year: 2021
  ident: CR27
  article-title: Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
  publication-title: Nat. Cancer
  contributor:
    fullname: Westcott
– volume: 48
  start-page: 812
  year: 2018
  end-page: 830.e14
  ident: CR12
  article-title: The Immune Landscape of Cancer
  publication-title: Immunity
  contributor:
    fullname: Thorsson
– volume: 363
  start-page: 711
  year: 2010
  end-page: 723
  ident: CR3
  article-title: Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
  publication-title: N. Engl. J. Med.
  contributor:
    fullname: Hodi
– volume: 290
  start-page: 2149
  year: 2003
  end-page: 2158
  ident: CR62
  article-title: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
  publication-title: JAMA
  contributor:
    fullname: Kris
– volume: 7
  start-page: 305
  year: 2019
  ident: CR47
  article-title: Mechanisms regulating PD-L1 expression on tumor and immune cells
  publication-title: J. Immunother. Cancer
  contributor:
    fullname: Chen
– volume: 24
  start-page: 1550
  year: 2018
  end-page: 1558
  ident: CR61
  article-title: Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
  publication-title: Nat. Med.
  contributor:
    fullname: Jiang
– volume: 397
  start-page: 375
  year: 2021
  end-page: 386
  ident: CR25
  article-title: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
  publication-title: Lancet
  contributor:
    fullname: Baas
– volume: 372
  start-page: 2018
  year: 2015
  end-page: 2028
  ident: CR9
  article-title: Pembrolizumab for the treatment of non-small-cell lung cancer
  publication-title: N. Engl. J. Med.
  contributor:
    fullname: Garon
– volume: 9
  start-page: 1708065
  year: 2020
  ident: CR28
  article-title: Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity
  publication-title: Oncoimmunology
  contributor:
    fullname: Kato
– volume: 21
  start-page: 3113
  year: 2015
  end-page: 3120
  ident: CR48
  article-title: Boosting cancer immunotherapy with anti-CD137 antibody therapy
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Kohrt
– volume: 20
  start-page: 95
  year: 2018
  end-page: 109
  ident: CR64
  article-title: Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors
  publication-title: J. Mol. Diagn.
  contributor:
    fullname: Conroy
– volume: 10
  start-page: 451
  year: 2010
  end-page: 458
  ident: CR59
  article-title: Galiximab: A review
  publication-title: Expert Opin. Biol. Ther.
  contributor:
    fullname: Czuczman
– volume: 362
  start-page: 2380
  year: 2010
  end-page: 2388
  ident: CR63
  article-title: Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
  publication-title: N. Engl. J. Med.
  contributor:
    fullname: Maemondo
– volume: 73
  start-page: 2468
  year: 2013
  end-page: 2479
  ident: CR55
  article-title: Interleukin 21-induced granzyme b-expressing b cells infiltrate tumors and regulate t cells
  publication-title: Cancer Res.
  contributor:
    fullname: Lindner
– volume: 372
  start-page: 2521
  year: 2015
  end-page: 2532
  ident: CR4
  article-title: Pembrolizumab versus ipilimumab in advanced melanoma
  publication-title: N. Engl. J. Med.
  contributor:
    fullname: Robert
– ident: CR65
– volume: 24
  start-page: 1785
  year: 2018
  end-page: 1794
  ident: CR8
  article-title: Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors
  publication-title: Clin. Cancer Res.
  contributor:
    fullname: Kurzrock
– volume: 10
  start-page: 2225
  year: 2019
  end-page: 2235
  ident: CR49
  article-title: CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN-γ
  publication-title: Thorac. Cancer
  contributor:
    fullname: Wang
– volume: 14
  start-page: 847
  year: 2015
  end-page: 856
  ident: CR11
  article-title: PD-L1 expression as a predictive biomarker in cancer immunotherapy
  publication-title: Mol. Cancer Ther.
  contributor:
    fullname: Kurzrock
– volume: 17
  start-page: 877
  year: 2021
  end-page: 892
  ident: CR7
  article-title: Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer
  publication-title: Futur. Oncol.
  contributor:
    fullname: Lheureux
– volume: 4
  start-page: e180013
  year: 2018
  ident: CR32
  article-title: Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial
  publication-title: JAMA Oncol.
  contributor:
    fullname: Fuchs
– volume: 17
  start-page: 2105
  year: 1999
  end-page: 2116
  ident: CR2
  article-title: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
  publication-title: J. Clin. Oncol.
  contributor:
    fullname: Atkins
– volume: 211
  start-page: 715
  year: 2014
  end-page: 725
  ident: CR52
  article-title: Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
  publication-title: J. Exp. Med.
  contributor:
    fullname: Allison
– volume: 31
  start-page: 1011
  year: 2020
  end-page: 1020
  ident: CR31
  article-title: Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas
  publication-title: Ann. Oncol.
  contributor:
    fullname: Derks
– volume: 12
  year: 2020
  ident: CR60
  article-title: Large-scale public data reuse to model immunotherapy response and resistance
  publication-title: Genome Med.
  contributor:
    fullname: Fu
– volume: 448
  start-page: 344
  year: 2006
  end-page: 353
  ident: CR41
  article-title: Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection
  publication-title: Virchows Arch.
  contributor:
    fullname: Chiaravalli
– volume: 395
  start-page: 1835
  year: 2020
  end-page: 1844
  ident: CR24
  article-title: Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet
  contributor:
    fullname: Gutzmer
– volume: 19
  start-page: 1189
  year: 2017
  end-page: 1201
  ident: CR46
  article-title: Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
  publication-title: Cell Rep.
  contributor:
    fullname: Garcia-Diaz
– volume: 15
  start-page: 104
  year: 2010
  ident: 359_CR1
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2009-0250
  contributor:
    fullname: J Summers
– volume: 11
  start-page: 851
  year: 2015
  ident: 359_CR26
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.1080/21645515.2015.1009814
  contributor:
    fullname: V Seledtsov
– volume: 17
  start-page: 877
  year: 2021
  ident: 359_CR7
  publication-title: Futur. Oncol.
  doi: 10.2217/fon-2020-0655
  contributor:
    fullname: L Kasherman
– volume: 24
  start-page: 1785
  year: 2018
  ident: 359_CR8
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-1970
  contributor:
    fullname: D Jardim
– volume: 16
  start-page: 2598
  year: 2017
  ident: 359_CR15
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-17-0386
  contributor:
    fullname: AM Goodman
– volume: 9
  start-page: 1708065
  year: 2020
  ident: 359_CR28
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2019.1708065
  contributor:
    fullname: S Kato
– volume: 31
  start-page: 1011
  year: 2020
  ident: 359_CR31
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2020.04.011
  contributor:
    fullname: S Derks
– volume: 77
  start-page: 2318
  year: 2017
  ident: 359_CR38
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-16-3346
  contributor:
    fullname: BM Larimer
– volume: 162
  start-page: 4983
  year: 1999
  ident: 359_CR58
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.162.8.4983
  contributor:
    fullname: XX Zheng
– volume: 58
  start-page: 236
  year: 1963
  ident: 359_CR30
  publication-title: J. Am. Stat. Assoc.
  doi: 10.1080/01621459.1963.10500845
  contributor:
    fullname: JH Ward
– volume: 21
  start-page: 1353
  year: 2020
  ident: 359_CR66
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(20)30445-9
  contributor:
    fullname: A Marabelle
– volume: 59
  start-page: 207
  year: 2011
  ident: 359_CR39
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.2011.03915.x
  contributor:
    fullname: P Salama
– volume: 141
  start-page: 293
  year: 2016
  ident: 359_CR43
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2016.03.008
  contributor:
    fullname: JR Webb
– volume: 372
  start-page: 2018
  year: 2015
  ident: 359_CR9
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1501824
  contributor:
    fullname: EB Garon
– volume: 8
  start-page: e000438
  year: 2020
  ident: 359_CR18
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2019-000438
  contributor:
    fullname: R Okamura
– volume: 67
  start-page: 1
  year: 2016
  ident: 359_CR50
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2016.06.028
  contributor:
    fullname: DA Knee
– volume: 66
  start-page: 127
  year: 2019
  ident: 359_CR53
  publication-title: Int. Immunopharmacol.
  doi: 10.1016/j.intimp.2018.10.045
  contributor:
    fullname: M Zhang
– volume: 73
  start-page: 2468
  year: 2013
  ident: 359_CR55
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-12-3450
  contributor:
    fullname: S Lindner
– volume: 19
  year: 2019
  ident: 359_CR45
  publication-title: BMC Cancer
  contributor:
    fullname: H Wang
– volume: 10
  start-page: 2225
  year: 2019
  ident: 359_CR49
  publication-title: Thorac. Cancer
  doi: 10.1111/1759-7714.13207
  contributor:
    fullname: H Wang
– volume: 362
  start-page: 2380
  year: 2010
  ident: 359_CR63
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa0909530
  contributor:
    fullname: M Maemondo
– volume: 379
  start-page: 2220
  year: 2018
  ident: 359_CR23
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1809064
  contributor:
    fullname: L Horn
– volume: 36
  start-page: 224
  year: 2013
  ident: 359_CR35
  publication-title: Am. J. Clin. Oncol. Cancer Clin. Trials
  doi: 10.1097/COC.0b013e3182467d90
  contributor:
    fullname: ST Kim
– ident: 359_CR67
  doi: 10.1016/S0140-6736(18)32409-7
– volume: 14
  start-page: 1680
  year: 2020
  ident: 359_CR19
  publication-title: Mol. Oncol.
  doi: 10.1002/1878-0261.12748
  contributor:
    fullname: TV Pham
– volume: 17
  start-page: 2105
  year: 1999
  ident: 359_CR2
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.1999.17.7.2105
  contributor:
    fullname: MB Atkins
– volume: 20
  start-page: 95
  year: 2018
  ident: 359_CR64
  publication-title: J. Mol. Diagn.
  doi: 10.1016/j.jmoldx.2017.10.001
  contributor:
    fullname: JM Conroy
– volume: 33
  start-page: 1753
  year: 2020
  ident: 359_CR51
  publication-title: Mod. Pathol.
  doi: 10.1038/s41379-020-0550-z
  contributor:
    fullname: MMT Zhu
– volume: 23
  start-page: 4473
  year: 2017
  ident: 359_CR40
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-2655
  contributor:
    fullname: JB Pakish
– volume: 31
  start-page: 1115
  year: 2020
  ident: 359_CR17
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2020.07.002
  contributor:
    fullname: V Subbiah
– volume: 397
  start-page: 375
  year: 2021
  ident: 359_CR25
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)32714-8
  contributor:
    fullname: P Baas
– volume: 10
  start-page: 451
  year: 2010
  ident: 359_CR59
  publication-title: Expert Opin. Biol. Ther.
  doi: 10.1517/14712591003596318
  contributor:
    fullname: S Bhat
– volume: 64
  start-page: 90
  year: 2017
  ident: 359_CR33
  publication-title: Semin Cell Dev. Biol.
  doi: 10.1016/j.semcdb.2016.09.008
  contributor:
    fullname: L Wang
– volume: 12
  start-page: 738
  year: 2020
  ident: 359_CR6
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12030738
  contributor:
    fullname: RK Vaddepally
– volume: 16
  start-page: 361
  year: 2019
  ident: 359_CR22
  publication-title: Nat. Rev. Gastroenterol. Hepatol.
  doi: 10.1038/s41575-019-0126-x
  contributor:
    fullname: K Ganesh
– volume: 8
  start-page: 1550341
  year: 2019
  ident: 359_CR20
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1550341
  contributor:
    fullname: A Boichard
– volume: 20
  year: 2021
  ident: 359_CR36
  publication-title: Mol. Cancer
  contributor:
    fullname: YP Chen
– volume: 39
  start-page: 154
  year: 2021
  ident: 359_CR16
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.10.001
  contributor:
    fullname: DL Jardim
– volume: 24
  start-page: 1550
  year: 2018
  ident: 359_CR61
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0136-1
  contributor:
    fullname: P Jiang
– volume: 363
  start-page: 711
  year: 2010
  ident: 359_CR3
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1003466
  contributor:
    fullname: FS Hodi
– volume: 383
  start-page: 2207
  year: 2020
  ident: 359_CR14
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2017699
  contributor:
    fullname: T André
– volume: 17
  start-page: 616
  year: 2010
  ident: 359_CR37
  publication-title: Cell Death Differ.
  doi: 10.1038/cdd.2009.206
  contributor:
    fullname: SP Cullen
– volume: 26
  start-page: 303
  year: 2008
  ident: 359_CR69
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt0308-303
  contributor:
    fullname: M Ringnér
– volume: 23
  start-page: 612
  year: 2022
  ident: 359_CR29
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(22)00128-0
  contributor:
    fullname: YA Vano
– volume: 19
  start-page: 1189
  year: 2017
  ident: 359_CR46
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2017.04.031
  contributor:
    fullname: A Garcia-Diaz
– volume: 184
  start-page: 596
  year: 2021
  ident: 359_CR13
  publication-title: Cell
  doi: 10.1016/j.cell.2021.01.002
  contributor:
    fullname: K Litchfield
– ident: 359_CR65
– volume: 61
  start-page: 1
  year: 2014
  ident: 359_CR68
  publication-title: J. Stat. Softw.
  doi: 10.18637/jss.v061.i06
  contributor:
    fullname: M Charrad
– ident: 359_CR54
  doi: 10.1093/bib/bbaa180
– volume: 48
  start-page: 812
  year: 2018
  ident: 359_CR12
  publication-title: Immunity
  doi: 10.1016/j.immuni.2018.03.023
  contributor:
    fullname: V Thorsson
– volume: 12
  year: 2020
  ident: 359_CR60
  publication-title: Genome Med.
  contributor:
    fullname: J Fu
– volume: 9
  start-page: 1760067
  year: 2020
  ident: 359_CR34
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2020.1760067
  contributor:
    fullname: Y Gao
– volume: 21
  start-page: 3113
  year: 2015
  ident: 359_CR48
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-0263
  contributor:
    fullname: A Yonezawa
– volume: 290
  start-page: 2149
  year: 2003
  ident: 359_CR62
  publication-title: JAMA
  doi: 10.1001/jama.290.16.2149
  contributor:
    fullname: MG Kris
– volume: 2
  start-page: 1071
  year: 2021
  ident: 359_CR27
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-021-00247-z
  contributor:
    fullname: PMK Westcott
– volume: 448
  start-page: 344
  year: 2006
  ident: 359_CR41
  publication-title: Virchows Arch.
  doi: 10.1007/s00428-005-0066-4
  contributor:
    fullname: AM Chiaravalli
– volume: 7
  start-page: 305
  year: 2019
  ident: 359_CR47
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-019-0770-2
  contributor:
    fullname: S Chen
– volume: 372
  start-page: 2521
  year: 2015
  ident: 359_CR4
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1503093
  contributor:
    fullname: C Robert
– volume: 211
  start-page: 715
  year: 2014
  ident: 359_CR52
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20130590
  contributor:
    fullname: X Fan
– volume: 14
  start-page: 847
  year: 2015
  ident: 359_CR11
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-14-0983
  contributor:
    fullname: SP Patel
– volume: 11
  start-page: a028480
  year: 2019
  ident: 359_CR44
  publication-title: Cold Spring Harb. Perspect. Biol.
  doi: 10.1101/cshperspect.a028480
  contributor:
    fullname: E Alspach
– volume: 44
  start-page: 973
  year: 2016
  ident: 359_CR56
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.04.020
  contributor:
    fullname: JH Esensten
– volume: 391
  start-page: 748
  year: 2018
  ident: 359_CR5
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)33297-X
  contributor:
    fullname: T Powles
– volume: 395
  start-page: 1835
  year: 2020
  ident: 359_CR24
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30934-X
  contributor:
    fullname: R Gutzmer
– volume: 14
  start-page: 857
  year: 2019
  ident: 359_CR42
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2019.01.024
  contributor:
    fullname: Z Gong
– volume: 355
  start-page: 1018
  year: 2006
  ident: 359_CR57
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa063842
  contributor:
    fullname: G Suntharalingam
– volume: 375
  start-page: 1823
  year: 2016
  ident: 359_CR10
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1606774
  contributor:
    fullname: M Reck
– volume: 6
  start-page: e1284719
  year: 2017
  ident: 359_CR21
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2017.1284719
  contributor:
    fullname: A Boichard
– volume: 4
  start-page: e180013
  year: 2018
  ident: 359_CR32
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2018.0013
  contributor:
    fullname: CS Fuchs
SSID ssj0001651129
Score 2.3441246
Snippet Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application of...
Abstract Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 19
SubjectTerms 631/114/2785
631/67/580
Apoptosis
Bioinformatics
Biomedical and Life Sciences
Biomedicine
Breast cancer
Cancer
CD137 antigen
CD27 antigen
CD28 antigen
CD40 antigen
CD80 antigen
CD86 antigen
Cytotoxicity
Gene Function
Gene Therapy
Granzyme B
Human Genetics
Immune checkpoint inhibitors
Immunotherapy
Internal Medicine
Lymphocytes T
Microsatellite instability
Mutation
Pancreatic cancer
PD-L1 protein
Serine proteinase
Statistical analysis
Transcriptomics
Tumor necrosis factor
Tumors
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hHhAXRCmPtAW5Ejew6mQcx-YGiKqq1J5aqTfLiW26h02q7u6Bf8_YyS67PMSFYxIrGs2MPZ_tmW8A3iWz-lp4nohbeOpxxU3UjnsjZadCU1W5KOzySp3fyIvb-nar1VfKCRvpgUfFnZrWeNE4HXSrZauMc-h87dHLsisxjGW-otraTOXTFZWBxFQlI1CfLlKkSsXIyDNtHdc7kSgT9v8JZf6eLPnLjWkORGfP4OmEINmnUfJ9eBT65_D4crojP4DZNU-n8ew-N-z6xpYpGuW1IRUgs3nKx3lYfGSzrVxyNkR6nq_6YR7YXcqQGcixAiF0RqCWfjV14pkGjUVb31_AzdnX6y_nfGqowLtalkvuEFWHLsqItVA-IkVIEb2PHRIu7FQtY9C1LsugYxODx1IpF7pGyxh160p8CXv90IfXwCqPXeuNFo13ZGFsTRCSVgtHEMc0ThXwfq1cez_yZth8343ajqawZAqbTWF1AZ-T_jcjE-d1fkGeYCdPsP_yhAKO19az00Rc2BR9CSI2aAo42XymKZQs4fowrPKYTHtfYgGvRmNvJMGmJkCMVQF6xw12RN390s_uMk03bXQFgT1RwIe1x_yU6--6OPwfujiCJ1V29UQ_fgx7y4dVeEPoadm-zRPlB1J2GLo
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgLouXRQFsFiRtYdTKO7XBBgKgqpHJqpb1Zjh_tHjZZ9nHg3zN2vLssr2Niy3L8jWe-2PMg5E2E1TXM0Zi4hcYaV7QNylDXcm6Fl3WdgsKuvonLG_510kzygdsyu1VudGJS1G6w8Yz8PKpRtPUS2g_z7zRWjYq3q7mExn3yoKrRlKM8y4ncnbGIRCdyrAwDdb6M9iqGJANNyeuo2rNHKW3_37jmny6Tv92bJnN08YQ8zjyy_DgCf0ju-f6IPLzKN-VPyfSaxjP5cp7Kdt2Wq2iTkoaIYcjlLHrlLJbvy-kvHuXlEPB5tu6HmS_vop_MgOLlkaeXSG1xqFyPJ3caQ7d-PCM3F1-uP1_SXFaB2oZXK2oAhAUTeICGCRcA7SQLzgULyA6taHjwqlFV5VWQwTuohDDeSsVDUJ2p4Dk56IfeH5OydmA71yomnUGcoWs946gzDBKdVhpRkLebxdXzMXuGTrfeoPQIhUYodIJCq4J8iuu_7RkzX6cXw-JW542k2651TBrlVad4J1pjwLjGgeOVrcDjICcb9HTejku9E56CvN4240aKSJjeD-vUJyW_r6AgL0awtzMB2SAthrogak8M9qa639JP71KybvzdZUj5WEHebSRmN69_r8XL_3_GK_KoTkIc04ufkIPVYu1PkR2turO0BX4CVVEPbA
  priority: 102
  providerName: ProQuest
– databaseName: SpringerOpen
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwEB1BkRAXxHcDBRmJG1gkGcd2uMGKqkIqp1bqzXJim-5hk6q7e-DfM3a8WwLlwDGxY1l-Y8-Lx_MM8C7C6prS8SjcwuMdV7wN2nLXCtFLr-o6JYWdfpcn5-LbRXORZXJiLswsfo_64zo6mJhDjDypzXF9F-6RD1bRmhdycbOfIhN1yHkxt3868z1Jov82Xvn38cg_YqTJ9Rw_goeZM7LPE8iP4Y4fnsD90xwVfwrLMx7339lVuqLrB9tE_5NWg5hyzFbxBM71-hNb_nZ6nI2BnlfbYVx5dhnPxIxkSp44OSMaS03lu3dypSlN6-czOD_-erY44fkKBd43otpwiyh7tEEEbErpApJPLINzoUdigr1sRPC60VXldVDBO6yktL5XWoSgO1vhczgYxsEfAqsd9p1rdamcJUyxa30paH2wRGpaZWUB73eDa64mpQyTItyozQSFIShMgsLoAr7E8d_XjCrX6QWBb_KkMW3XulJZ7XWnRSdba9G6xqETVV-hp0aOduiZPPXWJvpbIoUK2wLe7otp0kQk7ODHbaqThO4rLODFBPa-J6gaosBYF6BnZjDr6rxkWF4mYW76tS2J3pUFfNhZzE2__j0WL_-v-it4UCejjtLiR3Cwud7618SMNt2bNCV-AXuUCDo
  priority: 102
  providerName: Springer Nature
Title T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy
URI https://link.springer.com/article/10.1038/s41525-023-00359-8
https://www.ncbi.nlm.nih.gov/pubmed/37553332
https://www.proquest.com/docview/2847561739
https://search.proquest.com/docview/2848229013
https://pubmed.ncbi.nlm.nih.gov/PMC10409760
https://doaj.org/article/9b9d07a8e8b84b69aa3ad5d3d41c13e8
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6SFEovpe-6TRcXemuVtXdkWe6tWRJCYUMoCexNyJaULNT2so9D_31Hsr3N9nHpUZaQB82M5pM0D4APnq0mSwzziVuYr3HFCic1MwXnlbD5ZBKCwmaX4uKGf51n8wMQQyxMcNqvysVJ870-aRZ3wbdyWVfjwU9sfDWb0hEiITOajA_hkOzvvTN6uFkRAUT0ETIJyvHaWykfiIwspKxjvkof5hlBHZzsGaSQt_9vYPNPn8nfHk6DPTp_Ao97IBl_6Qh-Cge2eQYPZ_1T-XNYXDN_KR8vQ92u23jjjVLYInwcclx7t5zV-nO8uOdSHreO2vW2aWsb33lHmZbkyxJQjwnb0lR9QZ5-UBe79eMF3JyfXU8vWF9XgVUZTzdMI4oKteMOs0QYh2QoE2eMq5DgYSUy7qzMZJpa6XJnDaZCaFvlkjsnS53iSzhq2sa-hnhisCpNIZPcaGI0loVNOG0ampBOkWsRwcdhcdWyS5-hwrM3StVxRRFXVOCKkhGc-vXfjfSpr8OHdnWregFQRVmYJNfSylLyUhRaozaZQcPTKkVLkxwP3FO9Pq6VN8KEFHMsIni_6yZN8pzQjW23YUzIfp9iBK86Zu8oGYQlArknBnuk7veQ8IZs3YOwRvBpkJhfdP17Ld78_5_ewqNJkHWfe_wYjjarrX1H0GlTjkhf5vkIHpyeXV59o9ZUTEfhGmIUdOgnCUAdAA
link.rule.ids 230,314,727,780,784,864,885,2102,12056,21388,27924,27925,31719,31720,33744,33745,41120,42189,43310,43805,51576,53791,53793,73745,74302
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwEB5BVwIuiOcSWCBI3MBaJ-M4DhfEol0V2FYIdaW9WU5s7_bQpPRx4N9jO25LeR3bWJHrbzzz1Z75BuC1h1UXVBMv3EJ8jytSWaGIrhhruCnzPBSFjcZ8eME-XxaX8cBtGdMqNz4xOGrdNf6M_Ni7URfrS6zez78T3zXK367GFho34cArpxcDODg5HX_9tjtl4YFQxGoZiuJ46SOWL0pGEuTriNiLSEG4_29s88-kyd9uTkNAOrsHdyOTTD_00N-HG6Z9ALdG8a78IUwnxJ_Kp_PQuOsqXfmoFHyEL0ROZz4vZ7F8l05_ySlPO-s-z9ZtNzPptc-U6ZyBGcfUU0du3atiR544qC_e-vEILs5OJx-HJDZWIE3BshVRiLxBZZnFgnJt0UVKarW2DTp-2PCCWSMKkWVG2NIajRnnyjSlYNaKWmX4GAZt15onkOYam1pXgpZaOaSxrgxlzmsoR3WqUvEE3mwWV857_QwZ7r1RyB4K6aCQAQopEjjx678d6bWvwxfd4krGrSSrutK0VMKIWrCaV0qh0oVGzbImQ-NecrRBT8YNuZQ780ng1fax20oeCdWabh3GBPn7DBM47MHezgTLwhFjzBMQe2awN9X9J-30Osh1uz-81JE-msDbjcXs5vXvtXj6_5_xEm4PJ6Nzef5p_OUZ3MmDQXux8SMYrBZr89xxpVX9Im6In9ZzE8I
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Jb9QwFH6CqVRxQWUPLRAkbmCNEzuOwwVR6KgsHVWolXqznNhu5zDJMMuBf8-z45lh2I6JLcvx2774bQCvPFlNQQ3xhVuI73FFKic1MRXnjbBlnoeksLOxOL3kn6-Kqxj_tIhhlWudGBS16Rp_Rz70ahRtfcmqoYthEecfR-9m34nvIOU9rbGdxm3YQ6tI8wHsHZ-Mz79tb1xEABcxc4YyOVx46-UTlBkJpeyI3LFOoYj_35DnnwGUv3lRg3EaHcDdiCrT9z0b3INbtr0P-2fRb_4AJhfE39Cns9DE6zpdegsV9IVPSk6nPkZnvnibTn6JL087h8_TVdtNbXrjo2Y6ZDaLqD1FoItLxe48cVKfyPXjIVyOTi4-nJLYZIE0Bc-WRDMmGqYdd6ygwjiGVpM6Y1zDECs2ouDOykJmmZWudNawTAhtm1Jy52StM_YIBm3X2ieQ5oY1takkLY1GqrO6spSjBtEIe6pSiwRerw9XzfpaGir4wJlUPSkUkkIFUiiZwLE__81MXwc7vOjm1yqKlarqytBSSytryWtRac20KQwzPGsyZnGRozX1VBTOhdqyUgIvN8MoVp4SurXdKswJpfAzlsDjntibnbCyQJDM8gTkDhvsbHV3pJ3chNLd-PNLEQDSBN6sOWa7r3-fxdP_f8YL2EdZUF8_jb8cwp088LOvO34Eg-V8ZZ8hbFrWz6M8_ASfChfv
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=T-cell+priming+transcriptomic+markers%3A+implications+of+immunome+heterogeneity+for+precision+immunotherapy&rft.jtitle=Npj+genomic+medicine&rft.au=Miyashita%2C+Hirotaka&rft.au=Kurzrock%2C+Razelle&rft.au=Bevins%2C+Nicholas+J.&rft.au=Thangathurai%2C+Kartheeswaran&rft.date=2023-08-08&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2056-7944&rft.volume=8&rft.issue=1&rft_id=info:doi/10.1038%2Fs41525-023-00359-8&rft.externalDocID=10_1038_s41525_023_00359_8
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2056-7944&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2056-7944&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2056-7944&client=summon